Clinical Trials Sponsored by Teva Branded

Total 1290 results

Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications

Asthma

United States, Australia, Bulgaria, Canada, Croatia, Germany, Greece, Hungary, Ireland, Israel, New Zealand, Poland, Romania, Russian Federation, Serbia, South Africa, Spain, Ukraine, United Kingdom
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)

Optic Neuritis
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma

United States, Australia, Brazil, Canada, Mexico, New Zealand, Peru
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteoarthritis or Low Back Pain Who Require Opioid Treatment for an Extended Period of Time

Chronic Pain

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time

Chronic Pain

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Safety of New Formulation of Glatiramer Acetate (Song)

Relapsing Remitting Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma

Eosinophilic Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma

Eosinophilic Asthma

United States, Belgium, Colombia, Hungary, Israel, Poland, Sweden, Argentina, Brazil, Canada, France, Mexico, Netherlands
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics

Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma

Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies

Seasonal Allergic Rhinitis | SAR

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Absolute Bioavailability of Reslizumab in Healthy Subjects

Absolute Bioavailability

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate (ASSERT)

Relapsing Remitting Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline

Parkinson's Disease

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release Tablet

Pain

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)

Perennial Allergic Rhinitis

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome (PreCISe)

Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Comparison of a Needle-free Injection Method With a Needle-syringe Injection Method (T-jet®)

Growth Hormone Deficiency
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Effects of Tyramine in Patients Who Completed the PRESTO Study.

Parkinson's Disease
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline

Relapse Remitting Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Multicenter Trial for Adults With Partial Seizures

Epilepsy
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis

Relapsing Remitting Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients

Parkinson's Disease

United States
Maastricht University Medical Center
AstraZeneca; Teva Branded

Completed

The Anti-Inflammatory Effect of Extrafine HFA-Beclometasone Versus HFA-Fluticasone, by Means of Inflammometry

Asthma

Netherlands
Teva Branded Pharmaceutical Products R&D, Inc.

Recruiting

An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia

Schizophrenia

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Recruiting

Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old

Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Recruiting

Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia

Schizophrenia

China
Teva Branded Pharmaceutical Products R&D, Inc.

Recruiting

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

Asthma

United States, Canada
Teva Branded Pharmaceutical Products R&D, Inc.

Recruiting

A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease (RELIEVE UCCD)

Crohn Disease | Colitis, Ulcerative

United States, Bulgaria, Czechia, Hungary, Poland, Spain, Belgium, France, Italy, Japan, Norway, Slovakia, Germany, Canada, Ukraine, United Kingdom, Israel, Serbia
Teva Branded Pharmaceutical Products R&D, Inc.

Active, not recruiting

A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia (SOLARIS)

Schizophrenia

United States, Bulgaria, China, Romania, Turkey
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy

Cerebral Palsy, Dyskinetic

United States, Italy, Russian Federation, Spain, Denmark, Israel, Poland, Ukraine, United Kingdom
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Participants With Solid Tumors

Solid Tumors

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease (HART)

Huntington Disease

United States, Canada
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel (NEUGR-003)

Chemotherapy-induced Neutropenia

Bulgaria, Romania, Russian Federation, Serbia, Ukraine
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma (CONNECT2)

Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia (RISE)

Schizophrenia

United States, Bulgaria
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

Study of the Effect of a 5-Day Regimen of Study Drug on Peripheral Stem Cell Mobilization in Healthy Participants (GRANIX)

Healthy Participants

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma (CONNECT1)

Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo (ARPEGGIO)

Primary Progressive Multiple Sclerosis

United States, Canada, Germany, Italy, Netherlands, Poland, Russian Federation, Spain, Ukraine, United Kingdom
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency

Growth Hormone Deficiency

United States, Czechia, Germany, Greece, Hungary, Israel, Serbia, Slovakia, Slovenia
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Assessment of LBR-101 In Chronic Migraine

Chronic Migraine

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course

Relapsing Multiple Sclerosis

United States, Austria, Bulgaria, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Israel, Italy, Lithuania, Netherlands, Poland, Romania, Russian Federation, Serbia, Spain, Sweden, Turkey, Ukraine, United Kingdom
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis

United States, Bulgaria, Croatia, Czechia, Estonia, Georgia, Germany, Israel, Italy, Lithuania, North Macedonia, Poland, Romania, Russian Federation, Slovakia, South Africa, Spain, Ukraine
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives

Oral Contraceptive | Follicle Development | Ovarian Follicle | Follicle Count | Follicle Size

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Comparison of Two Bronchodilator Inhalers in Pediatric Asthmatics

Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Multinational Study to Evaluate the Effects of a 28-Day Oral Contraceptive on Hemostatic Parameters in Healthy Women

Oral Contraceptive | Hemostasis

Germany, Israel, Italy, Spain
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

Efficacy of QVAR vs Flovent Diskus on Small Airways in Poorly Controlled Asthmatic Adolescents/Adult Patients

Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Comparison of Two Bronchodilator Inhalers in Adolescents and Adults With Exercise-Induced Asthma

Exercise-induced Bronchospasm

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication

BiPolar

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors

Solid Tumors

United States

3

Subscribe